USFDA11 Jun 2025, 06:31 pm
Zydus Lifesciences Ltd Receives EIR for API Manufacturing Facility at Ankleshwar
AI Summary
Zydus Lifesciences Ltd has announced that it has received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its API manufacturing facility located at Ankleshwar. The inspection, which took place from 10th to 14th March 2025, has been classified as No Action Indicated (NAI), indicating that the facility meets the necessary standards. This disclosure is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key Highlights
- Zydus Lifesciences Ltd has received the EIR from the US FDA for its API manufacturing facility at Ankleshwar.
- The US FDA inspection, conducted from 10th to 14th March 2025, has been classified as No Action Indicated (NAI).
- This disclosure is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.